Taub Rebecca 4

What Happened Rebecca Taub, a director of Madrigal Pharmaceuticals (MDGL), received equity awards on June 17, 2026. The Form 4 reports a grant of 454 restricted stock units (RSUs) and a grant of 766 derivative awards (reported as a derivative grant). Both awards were reported at $0.00 (no purchase price) because they are compensatory grants, not open-market transactions.

Key Details

• Transaction date: 2026-06-17; Form 4 filed 2026-06-18 (timely).
• Awards: 454 RSUs (F1) and 766 derivative awards (reported as derivative/award).
• Price: $0.00 per share (compensatory grants); reported value on Form 4 = $0.
• Vesting: Both the RSUs and the derivative award vest on the earlier of (i) June 17, 2027, or (ii) the issuer’s 2027 annual meeting, provided Taub remains in service (see F1 and F3).
• Beneficial ownership note: Footnote F2 states the Reporting Person and her spouse are managing members of SQN, LLC and disclaims beneficial ownership of certain securities except to the extent of any pecuniary interest.
• Shares owned after the transaction: not specified in the provided filing.

Context These entries are compensatory grants (awards) to a director and do not represent purchases or sales in the open market. The derivative award appears to be an option-like instrument that vests 100% on the schedule noted; the filing does not indicate any immediate sale or cashless exercise. Grants like these are common for director compensation and do not by themselves indicate insider buying or selling sentiment.